Cadila Healthcare soars 31% in 2 days on USFDA nod for Perphenazine tablets

Zydus Cadila has received final approval from the United States Food and Drug Administration to market Perphenazine tablets USP, 2 mg, 4 mg, 8 mg and 16 mg

Shares of Cadila Healthcare  (Zydus Cadila) surged 17 per cent to Rs 367 on the BSE on Wednesday in intra-day trade. The company today said that it has initiated an accelerated research programme with multiple teams in India and Europe developing a vaccine for the novel coronavirus, 2019-nCoV (COVID-19) based on two approaches.

The company’s robust manufacturing facilities for producing recombinant antigens and measles containing vaccines would enable rapid ramping up of the production for both vaccine candidates, once the proof-of-concept is established, the company said on clarification on news report, COVID 19 - Cadila Healthcare claims to make